Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EQRX EQRx (EQRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get EQRx alerts: Email Address About EQRx Stock (NASDAQ:EQRX) 30 days 90 days 365 days Advanced Chart Ad InvestorPlace“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Get EQRx alerts:Sign Up Key Stats Today's Range$2.34▼$2.3450-Day Range$2.04▼$2.4752-Week Range$1.58▼$5.55VolumeN/AAverage Volume3.30 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.Read More… “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address EQRX Stock News HeadlinesAbsci Corporation Leverages AI For Rapid Drug Discovery And Promising PartnershipsJuly 28, 2024 | seekingalpha.com599 Cancer Monoclonal Antibody Collaboration and Licensing Deals Report and Directory 2016-2024May 7, 2024 | finance.yahoo.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comRevolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressFebruary 27, 2024 | finanznachrichten.deRevolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical ProgressFebruary 26, 2024 | uk.finance.yahoo.comAbCellera Biologics (ABCL) Q4 2023 Earnings Call TranscriptFebruary 21, 2024 | msn.comGubra AS GUBRAFebruary 1, 2024 | morningstar.comSee More Headlines Company Calendar Today9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EQRX CUSIPN/A CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees362Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.33% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio22.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.98Miscellaneous Outstanding Shares487,420,000Free Float398,218,000Market Cap$1.14 billion OptionableOptionable Beta0.48 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:EQRX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMike Huckabee Puts His Faith in This to Protect His RetirementMike Huckabee's Urgent Warning: Safeguard Your Financial Future NowAmerican Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EQRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.